Isomorphic Labs raises $5 billion with MGX participation to move its drugs into clinical trials
Listen to this article
Read by Anchor
Isomorphic Labs closed a Series C financing round of $5 billion, a massive funding step aimed at moving AI-designed drugs from computational simulation to human clinical trials. The round, in which UAE technology-investment firm MGX participated as an existing investor, reflects the accelerating shift of sovereign and private capital from generative-language software to predictive biology, as the cost of laboratory testing now exceeds that of traditional software and reaches the halls of major pharmaceutical labs.
Nobel-led chemical simulation:The company was founded after spinning out of DeepMind, the Alphabet subsidiary, in 2021, and is led by its founder Demis Hassabis, who left his role as CEO of DeepMind to focus entirely on drug discovery, remaining as chair of the research lab’s board. The firm’s drug-design engine is based on AlphaFold, the leading model for predicting protein three-dimensional structures from their genetic sequence alone, the scientific breakthrough for which Hassabis and John Gamble received the Nobel Prize in Chemistry. The platform now relies on a broad suite of intelligent computational-simulation models that explore multiple chemical dimensions to invent precise therapeutic compounds, already delivering positive results in pre-clinical trials in oncology and immunology.
Capital alliance and pharma giants:The new investment round was led by Green Oaks and Sequoia Capital, and saw the entry of Andersen Horowitz as a new investor, alongside full participation from the company’s existing backers, including Alphabet’s venture arms GV and Capital G, Thrive Capital, the Temasek fund, the UK sovereign AI fund, and MGX. This haul comes just months after the company raised $2.1 billion in a Series B round in May, earmarking the new money for developing the generative engine and tackling new drug classes. Although the firm has not disclosed an official valuation for this round, Bloomberg reports earlier this month that it was seeking a valuation near $50 billion, a target supported by its commercial partnerships with pharma giants such as Eli Lilly, Novartis and Johnson & Johnson.
Clinical field test:Moving into clinical trials represents the most costly and risky inflection point in a biotech firm’s pathway, because the ability to model proteins computationally does not necessarily translate into meeting safety and biological-effect standards inside the human body. The financing details show that simulation models are no longer merely a tool to accelerate laboratory hypotheses, but have become a financial commitment to produce tangible compounds with an approved manufacturing and human-testing pathway. This shift moves competition from merely measuring algorithmic accuracy to bearing the multi-year clinical-research bills.
What this means for the region
The presence of the UAE-based MGX among the ongoing backers of Isomorphic Labs confirms that sovereign-wealth investment strategies in the Gulf are now integrating AI into health-care and drug sectors, rather than limiting themselves to data-center computing or language models. This stake gives the region an early window onto predictive-medicine developments and strengthens the prospect of future links between global drug-design platforms and regional clinical-research centers.
For health institutions and research labs in the Gulf, Egypt and the Levant, the arrival of these models in clinics forces a rethink of local clinical and genetic data-collection mechanisms. Organizations that build advanced molecular records and databases compliant with bio-security standards will be the most ready to attract international clinical trials for digitally designed drugs, while those that lag face the risk of relying solely on purchasing ready-made therapies at high monopoly prices.
This trajectory requires hospital managers and regional health regulators to prepare for updating frameworks that approve algorithmically developed medicines, and to train medical talent to handle AI-driven testing protocols, ensuring that modern therapies align with regional genetic diversity before entering broad commercial production.